Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.35 |
| ▸ | IARS1 | P41252 | 1/20 | 0.34 |
| ▸ | MARS1 | P56192 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16417879 | 0.79 | LMNA (0.32) | LMNADOT1L | |
| SCHEMBL13375777 | 0.77 | SLC29A1 (0.46) | LMNAADORA1 | |
| SCHEMBL13930530 | 0.77 | SLC29A1 (0.46) | LMNAADORA1 | |
| SCHEMBL13897557 | 0.75 | HDAC1 (0.38) | IARS1MARS1ADORA1 | |
| SCHEMBL13951961 | 0.71 | KMT2A (0.40) | LMNAKMT2ACTSK | |
| SCHEMBL13897698 | 0.70 | CTSK (0.36) | KMT2ACTSK | |
| SCHEMBL16417876 | 0.68 | CDK5 (0.35) | DOT1LIARS1ADORA1CTSK | |
| SCHEMBL13952071 | 0.68 | CDK5 (0.35) | DOT1LADORA1CTSK | |
| SCHEMBL16256784 | 0.67 | KMT2A (0.49) | KMT2A | |
| SCHEMBL16256817 | 0.66 | KMT2A (0.52) | LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090053710-A1 | FUNCTIONAL MOLECULE, FUNCTIONAL MOLECULE SYNTHESIZING AMIDITE AND TARGET SUBSTANCE ANALYSIS METHOD | FUJITSU LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053710-A1 | FUNCTIONAL MOLECULE, FUNCTIONAL MOLECULE SYNTHESIZING AMIDITE AND TARGET SUBSTANCE ANALYSIS METHOD | TACR1, TACR2, ATIC | LMNA 2138/4885DOT1L 4426/4885IARS1 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.